AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15726094 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength estimates obtained by use of a Nicholas electronic dynamometer and range of motion in the standing position
Number of subjects: 108
Study 15726094 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI) and the University of Pennsylvania (UPenn) Shoulder Scale
Number of subjects: 108
Study 12799094 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily for 2 weeks, increased to 80 mg if BP remained >/=130/85 mm Hg)
Number of subjects: 2705
Study 12799094 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (titration from 40 mg to 80 mg)
Number of subjects: 2705
Study 12799094 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 2705
Study 10438995 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 51
Study 10438995 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH
Number of subjects: 51
Study 8571075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of ethanol
Number of subjects: 23
Study 8571075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of methanol
Number of subjects: 23
Study 8571075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-liquid chromatography (GC) for quantitative determination of acetone
Number of subjects: 23
Study 8571075 — intervention group
Group type: COMPARATOR
Intervention: Control specimens analyzed between 1987 and 1992
Number of subjects: 23
Study 8571075 — intervention group
Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 23
Study 2227222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil slow release (100 mg, twice daily)
Number of subjects: 15
Study 2227222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil immediate release (50 mg, four times daily)
Number of subjects: 15
Study 337985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral droperidol
Number of subjects: 87
Study 337985 — intervention group
Group type: COMPARATOR
Intervention: Oral droperidol plus diazepam
Number of subjects: 87
Study 337985 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (given to all patients)
Number of subjects: 87
Study 337985 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol syrup
Number of subjects: 87
Study 31226977 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement intervention
Number of subjects: 64
Study 31226977 — intervention group
Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 64
Study 28521109 — intervention group
Group type: EXPERIMENTAL
Intervention: 22,600 ppm fluoride varnish, toothbrush, a 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized prevention advice
Number of subjects: 1248
Study 28521109 — intervention group
Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 1248
Study 25594647 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable warming gown
Number of subjects: 94
Study 25594647 — intervention group
Group type: COMPARATOR
Intervention: Standard warming procedure
Number of subjects: 94
Study 23332800 — intervention group
Group type: EXPERIMENTAL
Intervention: yoghurt enriched with 3 g n‐3 LC‐PUFA/d
Number of subjects: 53
Study 23332800 — intervention group
Group type: EXPERIMENTAL
Intervention: yoghurt enriched with 0.8 g n‐3 LC‐PUFA/d
Number of subjects: 53
Study 23332800 — intervention group
Group type: COMPARATOR
Intervention: control yoghurt
Number of subjects: 53
Study 21214690 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐mefloquine paediatric (AS+MEF)
Number of subjects: 156
Study 21214690 — intervention group
Group type: COMPARATOR
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 156
Study 18053049 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine/sodium deoxycholate preparation
Number of subjects: 37
Study 18053049 — intervention group
Group type: COMPARATOR
Intervention: Sodium deoxycholate
Number of subjects: 37
Study 16427861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-blood cardioplegia enriched with N-acetylcysteine (50 mg per kilogram of body weight)
Number of subjects: 30
Study 16427861 — intervention group
Group type: COMPARATOR
Intervention: Cold-blood cardioplegia alone
Number of subjects: 30
Study 12637852 — intervention group
Group type: EXPERIMENTAL
Intervention: prehospital thrombolysis
Number of subjects: 16
Study 12637852 — intervention group
Group type: COMPARATOR
Intervention: usual hospital care
Number of subjects: 16
Study 10697448 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (2 sessions per week for 8 weeks)
Number of subjects: 38
Study 10697448 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (conventional community cares)
Number of subjects: 38
Study 9126183 — intervention group
Group type: EXPERIMENTAL
Intervention: UP + CB + weekly chlorhexidine rinse (CHX)
Number of subjects: 296
Study 9126183 — intervention group
Group type: EXPERIMENTAL
Intervention: UP + CB + CHX + semi‐annual fluoride varnish (F)
Number of subjects: 296
Study 9126183 — intervention group
Group type: EXPERIMENTAL
Intervention: UP + CB + CHX + F + semi‐annual prophylaxis, including scaling (P)
Number of subjects: 296
Study 9126183 — intervention group
Group type: COMPARATOR
Intervention: usual procedures (UP)
Number of subjects: 296
Study 9126183 — intervention group
Group type: COMPARATOR
Intervention: usual procedures (UP) + cognitive‐behavioral intervention (CB)
Number of subjects: 296
Study 8463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg tid for 12 weeks
Number of subjects: 7
Study 8463520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3948897 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg bolus followed by 2 mg/h continuous infusion for 8 h)
Number of subjects: 37
Study 3948897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29652169 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR group
Number of subjects: 77
Study 29652169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 26820385 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing care with the self-care model (4 visits: 2 in the first month, 2 in the next 2 months)
Number of subjects: 106
Study 26820385 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing care with the self-care model
Number of subjects: 106
Study 26820385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 106
Study 24746282 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Stretch
Number of subjects: 0
Study 24746282 — intervention group
Group type: COMPARATOR
Intervention: Split Skin Grafting (SSG)
Number of subjects: 0
Study 23116382 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle coaching (therapist followed and coached to increase healthy behaviors)
Number of subjects: 56
Study 23116382 — intervention group
Group type: COMPARATOR
Intervention: Emotional support (therapist followed and receiving only emotional support)
Number of subjects: 56
Study 23116382 — intervention group
Group type: COMPARATOR
Intervention: No therapist follow-up
Number of subjects: 56
Study 20855696 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer prevention intervention promoting sunless tanning
Number of subjects: 250
Study 20855696 — intervention group
Group type: COMPARATOR
Intervention: Control (surveys)
Number of subjects: 250
Study 19001195 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year multifactorial continued educational and behavioral program
Number of subjects: 3241
Study 19001195 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3241
Study 15737661 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 73
Study 15737661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15765628 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estradiol 1 mg/day plus intermittent norgestimate 90 microg/day
Number of subjects: 0
Study 15765628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestimate 90 microg/day
Number of subjects: 0
Study 10077716 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 130
Study 10077716 — intervention group
Group type: COMPARATOR
Intervention: Simple foot massage
Number of subjects: 130
Study 10077716 — intervention group
Group type: COMPARATOR
Intervention: Personal conversation
Number of subjects: 130
Study 7741138 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 19
Study 2297462 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 18
Study 2297462 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 18
Study 2297462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6793276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin-containing bone cement
Number of subjects: 1633
Study 6793276 — intervention group
Group type: COMPARATOR
Intervention: Systemically given antibiotics
Number of subjects: 1633
Study 31591965 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep-deprivation protocol
Number of subjects: 0
Study 31591965 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory neuroimaging
Number of subjects: 0
Study 31591965 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocannabinoid system (ECS) involvement
Number of subjects: 0
Study 29065193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg
Number of subjects: 40
Study 29065193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29065193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent smokers
Number of subjects: 40
Study 29065193 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional smokers
Number of subjects: 40
Study 29065193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 40
Study 26765470 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccine (YIC)
Number of subjects: 10
Study 24844551 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cooling with 4°C saline (Group I)
Number of subjects: 50
Study 24844551 — intervention group
Group type: COMPARATOR
Intervention: Mild hypothermic cardiopulmonary bypass (28‐32°C) without topical cooling (Group II)
Number of subjects: 50
Study 22540524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for three months (after initial oral bolus of 300 mg) together with aspirin 75 mg
Number of subjects: 250
Study 22540524 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg daily alone
Number of subjects: 250
Study 19595629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment (pramipexole)
Number of subjects: 12
Study 19595629 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment condition (no dopaminergic treatment)
Number of subjects: 12
Study 17337337 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 day communication course
Number of subjects: 0
Study 17337337 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 16261945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabal-urtica preparation PRO 160/120
Number of subjects: 0
Study 16261945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12123338 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP (gemcitabine 1000 mg/m2, epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Number of subjects: 27
Study 12123338 — intervention group
Group type: EXPERIMENTAL
Intervention: EP (epirubicin 90 mg/m2, paclitaxel 175 mg/m2)
Number of subjects: 27
Study 12123338 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone (90 mg/m2)
Number of subjects: 27
Study 12123338 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP
Number of subjects: 27
Study 12123338 — intervention group
Group type: EXPERIMENTAL
Intervention: EP
Number of subjects: 27
Study 9021203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.375 g of piperacillin-tazobactam intravenously every 6 hours
Number of subjects: 12
Study 9021203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g of piperacillin-tazobactam intravenously every 8 hours
Number of subjects: 12
Study 9021203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1 g of ticarcillin-clavulanate intravenously every 6 hours
Number of subjects: 12
Study 9021203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g of ampicillin-sulbactam intravenously every 6 hours
Number of subjects: 12
Study 9021203 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 12
Study 8113461 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0
Study 8113461 — intervention group
Group type: EXPERIMENTAL
Intervention: ELND with hyperthermic limb perfusion
Number of subjects: 0
Study 3351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally prepared milk‐free formulation (group A)
Number of subjects: 60
Study 3351705 — intervention group
Group type: COMPARATOR
Intervention: Spray dried commercial cow's milk formula (group B)
Number of subjects: 60
Study 29319050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweat Rate
Number of subjects: 136
Study 29319050 — intervention group
Group type: COMPARATOR
Intervention: Wet Bulb Globe Temperature (WBGT)
Number of subjects: 136
Study 29319050 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between Sweat Rate and WBGT
Number of subjects: 136
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine/tenofovir disoproxil fumarate for HIV prevention
Number of subjects: 312
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and partner discouragement regarding the study pill
Number of subjects: 312
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited acceptability of the pill's attributes
Number of subjects: 312
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about HIV-related stigma
Number of subjects: 312
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial's ancillary benefits and visit reimbursement
Number of subjects: 312
Study 26536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative patient-provider relationships
Number of subjects: 312
Study 24637965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein experimental formula (EXPL) with 1.65 g of protein/100 kcal
Number of subjects: 0
Study 24637965 — intervention group
Group type: COMPARATOR
Intervention: Control formula (CTRL) with 2.7 g of protein/100 kcal
Number of subjects: 0
Study 24637965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein experimental formula (EXPL)
Number of subjects: 0
Study 22231734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg orally 3 times daily for 6 weeks
Number of subjects: 0
Study 22231734 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally 3 times daily for 6 weeks
Number of subjects: 0
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI) medical composite score (ASImed)
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI) psychiatric composite score (ASIpsych)
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudesley Addiction Profile (MAP) physical health score (MAP-PHS)
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudesley Addiction Profile (MAP) mental health score (MAP-MHS)
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol visual analog scale (EQ-VAS)
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol Group's EQ-5D index score
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form SF-6D index score
Number of subjects: 251
Study 20236799 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization Disability Assessment Schedule‐II
Number of subjects: 251
Study 18371101 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (test sites)
Number of subjects: 13
Study 18371101 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary diamond burs (control sites)
Number of subjects: 13
Study 16466011 — intervention group
Group type: COMPARATOR
Intervention: Adiponectin level in type 2 diabetic patients
Number of subjects: 40
Study 16466011 — intervention group
Group type: COMPARATOR
Intervention: Fasting insulin, IL-6, TNFalpha, and HOMA-IR index in type 2 diabetic patients
Number of subjects: 40
Study 15507957 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 157
Study 15507957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 10707793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2/week for 4 weeks
Number of subjects: 120
Study 10707793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120
Study 10170451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder inhaler (Turbuhaler)
Number of subjects: 1004
Study 10170451 — intervention group
Group type: COMPARATOR
Intervention: Pressurised metered dose inhaler (pMDI)
Number of subjects: 1004
Study 8113480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (B)
Number of subjects: 15
Study 8113480 — intervention group
Group type: COMPARATOR
Intervention: Information-based therapy (A1)
Number of subjects: 15
Study 3533340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological ionisation with pirprofen (two-dose levels)
Number of subjects: 73
Study 3533340 — intervention group
Group type: COMPARATOR
Intervention: Sham ionisation
Number of subjects: 73
Study 3533340 — intervention group
Group type: COMPARATOR
Intervention: Placebo ionisation
Number of subjects: 73
Study 2972233 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium chloride (10 to 80 micrograms/kg)
Number of subjects: 81
Study 2972233 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 81
Study 2972233 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium (up to 2.7 times the ED95)
Number of subjects: 81
Study 30956126 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time ≤2 hours/day, physical activity before and/or during pregnancy, being born outside the United States
Number of subjects: 519
Study 30956126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prenatal diet quality
Number of subjects: 519
Study 30956126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary components (total vegetables, whole grains, dairy, fatty acids, refined grains, sodium, saturated fats, added sugars)
Number of subjects: 519
Study 27566696 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg vaginal misoprostol
Number of subjects: 126
Study 27566696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 26400825 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferral of PCI (Defer group)
Number of subjects: 325
Study 26400825 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of PCI (Perform group)
Number of subjects: 325
Study 26400825 — intervention group
Group type: COMPARATOR
Intervention: Reference group (PCI performed as planned)
Number of subjects: 325
Study 23812762 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for men, 0.55 g/kg for women)
Number of subjects: 22
Study 23812762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21893350 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative group (patients with recurrent adenotonsillitis)
Number of subjects: 47
Study 21893350 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative group (patients with recurrent adenotonsillitis)
Number of subjects: 47
Study 21893350 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 47
Study 20129547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1548
Study 20129547 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1548
Study 16439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg subcutaneously once daily for six to 14 days
Number of subjects: 849
Study 16439370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 16439370 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 849
Study 14749738 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-Carotene supplementation
Number of subjects: 17767
Study 14749738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17767
Study 14749738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 17767
Study 14749738 — intervention group
Group type: COMPARATOR
Intervention: Neither supplement
Number of subjects: 17767
Study 11346327 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental written self-disclosure protocol (three 20-minute writing sessions focusing on distressing experiences)
Number of subjects: 45
Study 11346327 — intervention group
Group type: COMPARATOR
Intervention: Control group (three 20-minute writing sessions focusing on health behaviors)
Number of subjects: 45
Study 9403285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine with food (750 mg)
Number of subjects: 20
Study 9403285 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine without food (750 mg)
Number of subjects: 20
Study 7912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of di‐Lex (III3FucnLc4) for 6 months
Number of subjects: 70
Study 7912285 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of tumor associated carbohydrate antigen (TCA) for 6 months
Number of subjects: 70
Study 7912285 — intervention group
Group type: COMPARATOR
Intervention: Intradermal injections of monomeric Lex
Number of subjects: 70
Study 3322351 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate responsive pacing (peak rate 125/min)
Number of subjects: 10
Study 3322351 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed rate pacing (VVI, 70/min)
Number of subjects: 10